WuXi Eyes A Fresh $1B, California Aims at AbbVie, and MSK’s Industry Ties in the Spotlight

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Allen’s $125M Bet on Immunology, Gilead’s New CEO, & Insulin Price-Gouging Scrutiny
CRISPR Babies, Ireland’s Bold Genomics Move, and a Flurry of FDA Approvals
Moderna’s Mega-IPO Plan, AbbVie Nails HCV, & SVB Takes Out Leerink
Sage Postpartum Depression Drug Passes Scrutiny, Blavatnik’s $200M Beneficence, & A Novartis Pricing Trial Balloon